Literature DB >> 6202391

Liver cell dysplasia and hepatitis B surface antigen in liver cirrhosis and hepatocellular carcinoma.

G Akagi, K Furuya, A Kanamura, T Chihara, H Otsuka.   

Abstract

Liver tissues of 223 autopsy cases of cirrhosis and hepatocellular carcinoma were examined for liver cell dysplasia in relation to hepatitis B surface antigen (HBsAg) detected with orcein stain. Liver cell dysplasia was found in 94 cases (42.2%): 37 were from cases of cirrhosis only, and 53 were from cases of cirrhosis with hepatocellular carcinoma. There was a significant difference in the overall incidence of HBsAg in cases with and without dysplasia (70.2%:32.6%). A similar difference was found in all groups, i.e., those with cirrhosis, cirrhosis with hepatocellular carcinoma, and hepatocellular carcinoma only, in which none of 11 cases of HBsAg negative had dysplasia. A good correlation was seen between the semiquantitative grade of dysplasia and the incidence of HBsAg. These findings suggest a close relationship of HBsAg with liver cell dysplasia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202391     DOI: 10.1002/1097-0142(19840715)54:2<315::aid-cncr2820540223>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation.

Authors:  A Marchio; B Terris; M Meddeb; P Pineau; A Duverger; P Tiollais; A Bernheim; A Dejean
Journal:  Mol Pathol       Date:  2001-08

Review 2.  Current treatment modalities for hepatocellular carcinoma.

Authors:  D G Farmer; M H Rosove; A Shaked; R W Busuttil
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

3.  Multifunctional light beam control device by stimuli-responsive liquid crystal micro-grating structures.

Authors:  J F Algorri; P Morawiak; D C Zografopoulos; N Bennis; A Spadlo; L Rodríguez-Cobo; L R Jaroszewicz; J M Sánchez-Pena; J M López-Higuera
Journal:  Sci Rep       Date:  2020-08-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.